311 related articles for article (PubMed ID: 17394196)
1. A small chimeric promoter for high prostate-specific transgene expression from adenoviral vectors.
Kraaij R; van der Weel L; de Ridder CM; van der Korput HA; Zweistra JL; van Rijswijk AL; Bangma CH; Trapman J
Prostate; 2007 Jun; 67(8):829-39. PubMed ID: 17394196
[TBL] [Abstract][Full Text] [Related]
2. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors.
Wu L; Matherly J; Smallwood A; Adams JY; Billick E; Belldegrun A; Carey M
Gene Ther; 2001 Sep; 8(18):1416-26. PubMed ID: 11571582
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer.
Li Y; McCadden J; Ferrer F; Kruszewski M; Carducci M; Simons J; Rodriguez R
Cancer Res; 2002 May; 62(9):2576-82. PubMed ID: 11980652
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
Latham JP; Searle PF; Mautner V; James ND
Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
6. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines.
Lee SE; Jin RJ; Lee SG; Yoon SJ; Park MS; Heo DS; Choi H
Anticancer Res; 2000; 20(1A):417-22. PubMed ID: 10769689
[TBL] [Abstract][Full Text] [Related]
7. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
Hsieh CL; Gardner TA; Miao L; Balian G; Chung LW
Cancer Gene Ther; 2004 Feb; 11(2):148-55. PubMed ID: 14695756
[TBL] [Abstract][Full Text] [Related]
8. Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations.
Suzuki S; Tadakuma T; Asano T; Hayakawa M
Cancer Res; 2001 Feb; 61(4):1276-9. PubMed ID: 11245419
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific targeting using PSA promoter-based lentiviral vectors.
Yu D; Chen D; Chiu C; Razmazma B; Chow YH; Pang S
Cancer Gene Ther; 2001 Sep; 8(9):628-35. PubMed ID: 11593331
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer.
Xie X; Zhao X; Liu Y; Zhang J; Matusik RJ; Slawin KM; Spencer DM
Cancer Res; 2001 Sep; 61(18):6795-804. PubMed ID: 11559553
[TBL] [Abstract][Full Text] [Related]
11. Expression of Drosophila Ca2+ permeable transient receptor potential-like channel protein in a prostate cancer cell line decreases cell survival.
Zhang L; Brereton HM; Hahn M; Froscio M; Tilley WD; Brown MP; Barritt GJ
Cancer Gene Ther; 2003 Aug; 10(8):611-25. PubMed ID: 12872143
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific adenoviral gene therapy: transcriptional repression of gene expression by utilizing p53-signal transduction pathways.
Kühnel F; Zender L; Wirth T; Schulte B; Trautwein C; Manns M; Kubicka S
Cancer Gene Ther; 2004 Jan; 11(1):28-40. PubMed ID: 14681724
[TBL] [Abstract][Full Text] [Related]
13. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells.
Chung I; Schwartz PE; Crystal RG; Pizzorno G; Leavitt J; Deisseroth AB
Cancer Gene Ther; 1999; 6(2):99-106. PubMed ID: 10195877
[TBL] [Abstract][Full Text] [Related]
14. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
Gotoh A; Ko SC; Shirakawa T; Cheon J; Kao C; Miyamoto T; Gardner TA; Ho LJ; Cleutjens CB; Trapman J; Graham FL; Chung LW
J Urol; 1998 Jul; 160(1):220-9. PubMed ID: 9628654
[TBL] [Abstract][Full Text] [Related]
15. A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression.
Rubinchik S; Wang D; Yu H; Fan F; Luo M; Norris JS; Dong JY
Mol Ther; 2001 Nov; 4(5):416-26. PubMed ID: 11708878
[TBL] [Abstract][Full Text] [Related]
16. Prostate-tumor targeting of gene expression by lentiviral vectors containing elements of the probasin promoter.
Yu D; Jia WW; Gleave ME; Nelson CC; Rennie PS
Prostate; 2004 Jun; 59(4):370-82. PubMed ID: 15065085
[TBL] [Abstract][Full Text] [Related]
17. Tightly-regulated suicide gene expression kills PSA-expressing prostate tumor cells.
Peng W; Chen J; Huang YH; Sawicki JA
Gene Ther; 2005 Nov; 12(21):1573-80. PubMed ID: 16034457
[TBL] [Abstract][Full Text] [Related]
18. Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system.
Koch PE; Guo ZS; Kagawa S; Gu J; Roth JA; Fang B
Mol Ther; 2001 Mar; 3(3):278-83. PubMed ID: 11273768
[TBL] [Abstract][Full Text] [Related]
19. Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model.
Gabril MY; Onita T; Ji PG; Sakai H; Chan FL; Koropatnick J; Chin JL; Moussa M; Xuan JW
Gene Ther; 2002 Dec; 9(23):1589-99. PubMed ID: 12424611
[TBL] [Abstract][Full Text] [Related]
20. Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area.
Kügler S; Kilic E; Bähr M
Gene Ther; 2003 Feb; 10(4):337-47. PubMed ID: 12595892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]